Home›Trial›NCT06128551
🔬NCT06128551Phase 1Phase 2RECRUITING

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Study Summary

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Conditions
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Interventions / Drugs
ElironrasibDaraxonrasib
View on ClinicalTrials.gov ↗
Sponsor
RVMD
Revolution Medicines
Precision Oncology
F35/100
Study Details
Enrollment534 participants
Primary Completion—
Lead SponsorRevolution Medicines, Inc.
Data Retrieved2026-04-11 04:26:28.070601+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.